Skip to main content
Log in

Antiretroviral Therapy for Prevention of Mother-to-Child HIV Transmission

Focus on Single-Dose Nevirapine

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Administration of potent antiretroviral combination therapy in the second and third trimester of pregnancy and during delivery, and for 6 weeks postpartum to the infant, may reduce HIV transmission from the mother to the child to <2% in formula-fed infants. In resource-constrained settings where women have limited access to antenatal care, use of shorter and more practical regimens, including nucleoside reverse transcriptase inhibitors (NRTIs) and/or non-NRTIs (NNRTIs) commenced later in pregnancy, has demonstrated efficacies ranging from 18% to 70% in breast- and bottle-fed populations. Because shorter interventions include regimens such as single-dose nevirapine or zidovudine monotherapy, which do not provide maximal suppression of viral replication, emergence of resistant mutations in mother and infant occurs frequently, primarily after exposure to drugs with low genetic barriers (i.e. those requiring only one genotypic mutation to develop resistance), such as nevirapine.

Different studies have reported nevirapine resistance rates ranging from 25% to 69% in mothers receiving single-dose nevirapine alone. Because NNRTI-based combinations of antiretroviral agents are recommended as first-line therapy in countries where single-dose nevirapine is the main option for preventing mother-to-child transmission of HIV, concerns have been raised as to whether single-dose nevirapine prophylaxis can compromise the efficacy of subsequent NNRTI-based antiretroviral therapy regimens. However, although some studies have shown that nevirapine exposure may impact on short-term virological outcome, the clinical relevance of nevirapine resistance remains unclear, especially in women who start treatment >6 months after delivery or in those who are not severely immunocompromised. Furthermore, studies have shown that adding short-course (up to 7 days) zidovudine or zidovudine/lamivudine prophylaxis after delivery may dramatically reduce the occurrence of nevirapine resistance in both mothers and infants.

Until data are available that allow a better understanding of the relevance of antiretroviral drug resistance acquired as a result of mother-to-child HIV transmission prophylaxis, women and children who have previously received single-dose nevirapine as part of a mother-to-child transmission prevention strategy should be considered eligible for NNRTI-based regimens and should not be denied access to antiretroviral therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. WHO/UNAIDS. AIDS epidemic update. December 2005 [online]. Available from URL: http://www.unaids.org/epi/2005/doc/report_pdf.asp [Accessed 2006 Aug 1]

  2. De Cock K, Fowler MG, Mercier E, et al. Prevention of mother to child HIV transmission in resource poor countries: translating research into policy and practice. JAMA 2000; 283: 1175–82

    Article  PubMed  Google Scholar 

  3. John-Stewart G, Mbori-Ngacha D, Ekpini R, et al. Breastfeeding and transmission of HIV-1. J Acquir Immune Defic Syndr 2004; 35: 196–202

    Article  PubMed  Google Scholar 

  4. Connor E, Sperling R, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173–80

    Article  PubMed  CAS  Google Scholar 

  5. World Health Organization. HIV transmission through breastfeeding: a review of available evidence: 2004 [online]. Available from URL: http://www.who.int/reproductive-health/docs/hiv_infantfeeding/breastfeeding.pdf [Accessed 2006 Oct 9]

  6. PHSTF/CDC. Recommendations for use of antiretroviral drugs in pregnant HIV 1 infected women for maternal health and intervention to reduce perinatal HIV transmission in the United States. AIDS info website [online]. Available from URL: http://www.AIDSinfo.nih.gov [Accessed 2005 Nov 1]

  7. Mofenson LM, Lambert JS, Stihem R, et al. Risk factors for perinatal transmission of HIV [abstract no. 1229]. In: Proceedings of the XIII AIDS Conference; 2000 Jul 9–14; Durban, South Africa

  8. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288: 189–98

    Article  PubMed  CAS  Google Scholar 

  9. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 2001; 183: 539–45

    Article  PubMed  CAS  Google Scholar 

  10. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet 1999; 353: 781–5

    Article  PubMed  CAS  Google Scholar 

  11. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. Diminution de la Transmission Mere-Enfant. Lancet 1999; 353(9155): 786–92

    Article  PubMed  CAS  Google Scholar 

  12. The Petra study team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomized, double-blind, placebo-controlled trial. Lancet 2002; 359: 1178–86

    Article  Google Scholar 

  13. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795–802

    PubMed  CAS  Google Scholar 

  14. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early post-partum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725–35

    Article  PubMed  CAS  Google Scholar 

  15. Dabis F, Bequet L, Ekouevi DK, et al. ANRS 1201/1202 DITRAME PLUS Study Group. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19: 309–18

    PubMed  Google Scholar 

  16. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353: 773–80

    Article  PubMed  CAS  Google Scholar 

  17. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000; 343(14): 982–91

    Article  PubMed  CAS  Google Scholar 

  18. Lallemant M, Jourdain G, Le Coeur S, et al. A randomized, double-blind trial assessing the efficacy of single-dose perinatal nevirapine added to a standard zidovudine regimen for the prevention of mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217–28

    Article  PubMed  Google Scholar 

  19. Lallemant M. Prevention of mother to child transmission of HIV [online]. Available from URL: http://www.pentatrials.org [Accessed 2005 Aug 1]

  20. Quaghebeur A, Mutunga L, Mwanyumba F, et al. Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation. AIDS 2004; 18: 1854–6

    Article  PubMed  Google Scholar 

  21. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the post-partum period after intrapartum single dose nevirapine in addition to zidovudine prophylaxis for prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005; 38: 283–8

    PubMed  CAS  Google Scholar 

  22. Chung MH, Kiarie JN, Richardson BA, et al. Breast milk HIV-1 suppression and decreased transmission: a randomised trial comparing HIVNET 012 nevirapine versus short course zidovudine. AIDS 2005; 19: 1415–22

    Article  PubMed  CAS  Google Scholar 

  23. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS 2005; 19: 1865–75

    Article  PubMed  Google Scholar 

  24. UNAIDS. Available from URL: http://www.womenandaids.unaids.org/issues_access.html [Accessed 2006 Sep 11]

  25. Chi BH, Wang L, Read JS, et al. Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024. AIDS 2005; 19: 1857–64

    Article  PubMed  CAS  Google Scholar 

  26. Jackson JB, Parsons T, Musoke P, et al. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. AIDS 2006; 20: 217–22

    PubMed  CAS  Google Scholar 

  27. 25.Eure C, Bakaki P, McConnell M, et al. Effectiveness of repeat single-dose nevirapine in subsequent pregnancies among Ugandan women [abstract no. 125]. 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, USA

  28. 26. Martinson N, Ekouevi D, Gray G, et al. Effectiveness of single-dose nevirapine in consecutive pregnancies in Soweto and Abidjan [abstract no. 722]. 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, USA

  29. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in paediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177: 557–64

    Article  PubMed  CAS  Google Scholar 

  30. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic ZDV drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Group. AIDS 2000; 14: 263–71

    Article  PubMed  CAS  Google Scholar 

  31. Mofenson LM, Lambert JS, Stihem R, et al. Risk factors for perinatal transmission of HIV [abstract no. 1229]. In: Proceedings of the XIII AIDS Conference; 2000 Jul 9–14; Durban, South Africa

  32. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in HIV infected pregnant women. J Infect Dis 1999; 179: 705–8

    Article  PubMed  CAS  Google Scholar 

  33. Sitniskaya Y, Rochford G, Rigaud M, et al. Prevalence of T215Y mutation in HIV-1 infected pregnant women in a New York cohort, 1995–1999. Clin Infect Dis 2001; 33: e3–7

    Article  Google Scholar 

  34. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant HIV-1 infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001; 184: 1120–6

    Article  PubMed  CAS  Google Scholar 

  35. Ekpini RA, Nkengasong JN, Sibailly T, et al. Changes in plasma HIV-1-RNA viral load and CD4+ cell counts, and lack of zidovudine resistance among pregnant women receiving shortcourse zidovudine. AIDS 2002; 16: 625–30

    Article  PubMed  CAS  Google Scholar 

  36. Giuliano M, Palmisano L, Galluzza C, et al. Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS 2003; 17: 1570–3

    Article  PubMed  Google Scholar 

  37. Colgrove RC, Pitt J, Chung PH, et al. Selective vertical transmission of HIV-1 antiretroviral resistance mutations AIDS 1998; 12: 2281–8

    CAS  Google Scholar 

  38. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine and zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083–93

    Article  PubMed  CAS  Google Scholar 

  39. WHO. Scaling up ART in resource-limited settings: treatment guidelines for a public health approach; 2003 revision. Geneva, Switzerland: 2004

  40. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months of follow up of the HIVNET012 randomised trial. Lancet 2003; 362: 859–68

    Article  PubMed  CAS  Google Scholar 

  41. Eshleman SH, Guay LA, Mwatha A, et al. Characterisation of nevirapine (NVP) resistance mutations in women with subtype A vs D in HIV-1, 6–8 weeks after single dose NVP (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35: 126–30

    Article  PubMed  CAS  Google Scholar 

  42. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of NVP resistance in Ugandan women 7 days vs. 6–8 weeks after single dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20: 595–9

    Article  PubMed  CAS  Google Scholar 

  43. Eshleman SH, Mwatha A, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951–7

    Article  PubMed  CAS  Google Scholar 

  44. Loubser S, Balfe P, Sherman G, et al. Sensitive real-time PCR quantification of 103N resistance mutants following single dose treatment with nevirapine [abstract no. 102]. In: Proceedings of the 12th Retrovirus Conference; 2005; Boston, USA

  45. Johnson J, Li JF, Morris L, et al. Emergence of drug resistance HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated J Infect Dis 2005; 192: 16–23

    CAS  Google Scholar 

  46. Flys T, Nissley DV, Claesen CW, et al. Sensitive drug-resistance assay reveals long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single dose NVP: HIVNET 012. J Infect Dis 2005; 192: 24–9

    Article  PubMed  CAS  Google Scholar 

  47. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine resistance in women with HIV-1 subtype C compared with subtype A and D after the administration of single-dose nevirapine. J Infect Dis 2005; 192: 30–6

    Article  PubMed  CAS  Google Scholar 

  48. Lee EJ, Kantor R, Zijenah L, et al. Breast milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis 2005; 192: 1260–4

    Article  PubMed  CAS  Google Scholar 

  49. Sullivan J. South African Intrapartum Nevirapine Trial: selection of resistance mutations [abstract no. LbPeB9024]. XVI International Conference on AIDS; 2002 Jul 7–12; Barcelona, Spain

  50. Shapiro R, Thior I, Gilbert P, et al. Maternal single dose nevirapine may not be needed to reduce mother-to-child HIV transmission in the setting of maternal and infant zidovudine and infant single dose nevirapine: results of a randomised clinical trial in Botswana [abstract no. 74LB]. In: Proceedings of the 12th Retrovirus Conference; 2005; Boston, USA

  51. McIntyre JA, Martinson N, Gray G, et al. Addition of short course Combivir (CBV) to single dose Viramune (SD-NVP) for the prevention of mother-to-child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI resistant virus [abstract no. TuFo0204]. In: Proceedings of the 3rd IAS Conference; 2005; Rio de Janeiro, Brazil

  52. Chaix ML, Dabis F, Ekouevi D, et al. Addition of ZDV+3TC post-partum to short course of ZDV+3TC and single dose nevirapine provides low rate of NVP resistance mutations and high efficacy in preventing HIV-1 transmission: ANRS DITRAME Plus. Abidjan, Cote d’Ivoire [abstract no. 72LB]. In: Proceedings of the 12th Retrovirus Conference; 2005; Boston, USA

  53. Palombi L, Germano P, Liotta G, et al. HAART in pregnancy: safety, effectiveness and protection from viral resistance: results from the DREAM cohort [abstract no. 67]. 12th Retrovirus Conference; 2005; Boston, USA

  54. Lyons F, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19: 63–7

    Article  PubMed  Google Scholar 

  55. Martinson N, Morris L, Gray G, et al. HIV resistance following single-dose nevirapine in pMTCT cohort [abstract no. 38]. In: Proceedings of the 11th Retrovirus Conference; 2004; San Francisco, USA

  56. Arrivè E, Dabis F, Newell ML, et al. Frequency of nevirapine resistance (NVPR) after single dose nevirapine (SD-NVP) use to prevent HIV-1 vertical transmission: a meta-analysis [abstract no. TuPe5.2P15]. In: Proceedings of the 3rd IAS Conference; 2005; Rio de Janeiro, Brazil

  57. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351: 229–40

    Article  PubMed  CAS  Google Scholar 

  58. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomised controlled trial. JAMA 2004; 292: 202–9

    Article  PubMed  CAS  Google Scholar 

  59. Mironchnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in HIV type 1 infected pregnant women and their neonates. PACTG 250 team. J Infect Dis 1998; 178: 368–74

    Article  Google Scholar 

  60. Musoke P, Guay LA, Beganda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant Ugandan women and their neonates. AIDS 1999; 13: 479–86

    Article  PubMed  CAS  Google Scholar 

  61. Brenner B, Turner D, Oliveira M, et al. V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non nucleoside reverse transcriptase inhibitors. AIDS 2003; 8: F1–5

    Article  Google Scholar 

  62. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact on HIV-1 subtype in women receiving single dose NVP prophyIaxis to prevent HIV vertical transmission (HIVNET 012). J Infect Dis 2001; 184: 914–7

    Article  PubMed  CAS  Google Scholar 

  63. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. J Acquir Immune Defic Syndr 2005; 39(5): 593–7

    PubMed  Google Scholar 

  64. Gray G, McIntyre J, Hopley M, et al. NNRTI-resistant mutations in HIV-1 infected infants following single dose nevirapine (SD-NVP) are reduced by addition of short course zidovudine and 3TC [abstract no. TuPe5.4P01]. In: Proceedings of the 3rd IAS Conference; 2005; Rio de Janeiro, Brazil

  65. Ngo-Giang-Huong, Jourdain G, Tungyai P, et al. Infant zidovudine prophylaxis and emergence of nevirapine resistance at 6 weeks in perinatally HIV-infected infants exposed to intrapartum or newborn nevirapine [abstract no. 802]. In: Proceedings of the 12th Retrovirus Conference; 2005; Boston, USA

  66. Eshelman SH, Hoover DR, Chen S, et al. Resistance after single dose nevirapine prophylaxis emerges in high proportion of Malawian newborn. AIDS 2005; 19: 2167–9

    Article  Google Scholar 

  67. Hammer SM. Single-dose nevirapine and drug resistance: the more you look, the more you find. J Infect Dis 2005; 192: 1–3

    Article  PubMed  Google Scholar 

  68. Lallemant M. Response to therapy after prior exposure to nevirapine [abstract no. TuFo0205]. In: Proceedings of the 3rd IAS Conference; 2005; Rio de Janeiro, Brazil

  69. Bedikou G, Viho I, Tonwe-Gold B, et al. 6-months immunological response with HAART containing nevirapine in HIV-infected women post exposure to single dose nevirapine for PMTCT. The MTCT Plus Initiative in Abidjan, Cote d’Ivoire (2003–2005) [abstract no. MaOa0203]. In: Proceedings of the 3rd IAS Conference; 2005; Rio de Janeiro, Brazil

  70. Lockman S, Smeaton L, Shapiro R, et al. Maternal and infant response to nevirapine (NVP) based ART following peripartum single-dose NVP [abstract no. LB5]. In: Proceedings of the 43rd IDSA; 2005; San Francisco, USA

  71. Coovadia A, Marais B, Abrams E, et al. Virologic response to NNRTI treatment among women who took single dose nevirapine 18 to 36 months earlier [abstract no. 641]. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, USA

  72. Chi B, Sinkala M, Levy J, et al. Maternal immune response and clinical outcomes on NNRTI-based antiretroviral therapy (ART) following exposure to single dose Nevirapine (NVP) for prevention of mother to child transmission (PMTCT) [abstract no. WEAB0104]. In: Proceedings of the XVI International AIDS Conference; 2006 Aug; Toronto

  73. MacKie NE, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004; 5: 180–4

    Article  PubMed  CAS  Google Scholar 

  74. Palmer S, Boltz V, Maldarelli F, et al. Short-course Combivir (CBV) single dose nevirapine reduces but does not eliminate the selection of nevirapine-resistant HIV-1: improved detection by allele-specific PCR [abstract no. 3]. Antiviral Ther 2005; 10: S5

    Google Scholar 

  75. WHO. Guidelines on the use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Geneva, Switzerland, 2006 [online]. Available from URL: (rs hhttp://www.who.int/hiv/pub/guidelines/pmtct/en/index.html [Accessed 2006 Sep 30]

Download references

Acknowledgements

This review was supported by an educational grant from Boehringer-Ingelheim, Italy. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carlo Giaquinto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giaquinto, C., Rampon, O. & De Rossi, A. Antiretroviral Therapy for Prevention of Mother-to-Child HIV Transmission. Clin. Drug Investig. 26, 611–627 (2006). https://doi.org/10.2165/00044011-200626110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626110-00001

Keywords

Navigation